Literature DB >> 9933442

Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells.

H Vallin1, S Blomberg, G V Alm, B Cederblad, L Rönnblom.   

Abstract

Patients with active SLE often have an ongoing production of IFN-alpha. We therefore searched for an endogenous IFN-alpha-inducing factor (IIF) in SLE patients and found that their sera frequently induced production of IFN-alpha in cultures of peripheral blood mononuclear cells (PBMC) from healthy blood donors, especially when the PBMC were costimulated with the cytokines IFN-alpha2b and granulocyte-macrophage colony-stimulating factor (GM-CSF). The phenotype of the IFN-alpha-producing cells (IPC) as determined by flow cytometry corresponded to that of the natural IPC, resembling immature dendritic cells. The IIF activity in SLE sera was sometimes as high as that of a virus and was present especially in patients with active disease and with measurable IFN-alpha levels in serum. The IIF had an apparent molecular weight of 300-1000 kD and appeared to consist of both immunoglobulin and DNA, possibly being immune complexes. This endogenous IFN-alpha inducer may be of pathogenic significance, since a reported occasional adverse effect of IFN-alpha therapy in patients with non-autoimmune disorders is development of anti-dsDNA antibodies and SLE.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9933442      PMCID: PMC1905199          DOI: 10.1046/j.1365-2249.1999.00772.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily.

Authors:  L J Zhou; R Schwarting; H M Smith; T F Tedder
Journal:  J Immunol       Date:  1992-07-15       Impact factor: 5.422

2.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

3.  Serum levels of interferons in patients with systemic lupus erythematosus.

Authors:  T Kim; Y Kanayama; N Negoro; M Okamura; T Takeda; T Inoue
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

4.  Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors.

Authors:  L E Rönnblom; G V Alm; K E Oberg
Journal:  Ann Intern Med       Date:  1991-08-01       Impact factor: 25.391

5.  Antibody binding of macromolecular DNA and RNA in the plasma of SLE patients.

Authors:  F Krapf; M Herrmann; W Leitmann; J R Kalden
Journal:  Clin Exp Immunol       Date:  1989-03       Impact factor: 4.330

6.  Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour.

Authors:  L E Rönnblom; G V Alm; K E Oberg
Journal:  J Intern Med       Date:  1990-03       Impact factor: 8.989

7.  Interferons and the colony-stimulating factors IL-3 and GM-CSF enhance the IFN-alpha response in human blood leucocytes induced by herpes simplex virus.

Authors:  B Cederblad; G V Alm
Journal:  Scand J Immunol       Date:  1991-11       Impact factor: 3.487

8.  Deficient herpes simplex virus-induced interferon-alpha production by blood leukocytes of preterm and term newborn infants.

Authors:  B Cederblad; T Riesenfeld; G V Alm
Journal:  Pediatr Res       Date:  1990-01       Impact factor: 3.756

9.  Infrequent but efficient interferon-alpha-producing human mononuclear leukocytes induced by herpes simplex virus in vitro studied by immuno-plaque and limiting dilution assays.

Authors:  B Cederblad; G V Alm
Journal:  J Interferon Res       Date:  1990-02

10.  MX homologous protein in mononuclear cells from patients with systemic lupus erythematosus.

Authors:  P von Wussow; D Jakschies; H Hochkeppel; M Horisberger; K Hartung; H Deicher
Journal:  Arthritis Rheum       Date:  1989-07
View more
  69 in total

Review 1.  The plasmacytoid monocyte/interferon producing cells.

Authors:  Fabio Facchetti; William Vermi; David Mason; Marco Colonna
Journal:  Virchows Arch       Date:  2003-10-28       Impact factor: 4.064

2.  Multiple sclerosis-linked and interferon-beta-regulated gene expression in plasmacytoid dendritic cells.

Authors:  Latt Latt Aung; Andrew Brooks; Steven A Greenberg; Michael L Rosenberg; Suhayl Dhib-Jalbut; Konstantin E Balashov
Journal:  J Neuroimmunol       Date:  2012-06-09       Impact factor: 3.478

3.  Systemic sclerosis and lupus: points in an interferon-mediated continuum.

Authors:  Shervin Assassi; Maureen D Mayes; Frank C Arnett; Pravitt Gourh; Sandeep K Agarwal; Terry A McNearney; Damien Chaussabel; Nancy Oommen; Michael Fischbach; Kairav R Shah; Julio Charles; Virginia Pascual; John D Reveille; Filemon K Tan
Journal:  Arthritis Rheum       Date:  2010-02

4.  Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus.

Authors:  Di Feng; Rivka C Stone; Maija-Leena Eloranta; Niquiche Sangster-Guity; Gunnel Nordmark; Snaevar Sigurdsson; Chuan Wang; Gunnar Alm; Ann-Christine Syvänen; Lars Rönnblom; Betsy J Barnes
Journal:  Arthritis Rheum       Date:  2010-02

Review 5.  [Type I interferonopathies. Systemic inflammatory diseases triggered by type I interferons].

Authors:  C Günther; F Schmidt; N König; M A Lee-Kirsch
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

Review 6.  Manifold mechanisms of Toll-like receptor-ligand recognition.

Authors:  Ken J Ishii; Cevayir Coban; Shizuo Akira
Journal:  J Clin Immunol       Date:  2005-11       Impact factor: 8.317

Review 7.  Dendritic cells: potential triggers of autoimmunity and targets for therapy.

Authors:  J A Hardin
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 8.  Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics.

Authors:  Romain Banchereau; Alma-Martina Cepika; Jacques Banchereau; Virginia Pascual
Journal:  Annu Rev Immunol       Date:  2017-01-30       Impact factor: 28.527

9.  Essential requirement for IRF8 and SLC15A4 implicates plasmacytoid dendritic cells in the pathogenesis of lupus.

Authors:  Roberto Baccala; Rosana Gonzalez-Quintial; Amanda L Blasius; Ivo Rimann; Keiko Ozato; Dwight H Kono; Bruce Beutler; Argyrios N Theofilopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

10.  Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus.

Authors:  Danika Schepis; Iva Gunnarsson; Maija-Leena Eloranta; Jon Lampa; Stefan H Jacobson; Klas Kärre; Louise Berg
Journal:  Immunology       Date:  2008-06-18       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.